PMGC Holdings Announces Term Sheet with Orbit2Orbit for NorthStrive Biosciences to Launch a Spaceflight Study of Its Myostatin and Activin A Assets, EL-22 and EL-32, Targeting Microgravity-Induced Muscle Loss

PMGC Holdings announced a term sheet with Orbit2Orbit to launch a spaceflight study for NorthStrive Biosciences’ Myostatin and Activin A assets (EL-22). The agreement is incremental but constructive for pipeline development, with limited detail provided on scope, timelines, or funding terms. Overall, this signals continued progress in advancing key biotech assets via a platform partnership.